Pearl Therapeutics Inc., of Redwood City, Calif., reported data from a Phase IIb study of formoterol fumarate metered dose inhaler (FF MDI; PT005), a long-acting beta-2 agonist, compared to placebo and Foradil Aerolizer (Novartis AG) in patients with moderate to severe chronic obstructive pulmonary disease.